MYM Nutraceuticals to develop the cannabis “gold standard” for product testing process and technology in Canada.
Vancouver, British Columbia, Canada, April 4th, 2017 – MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMS)(FRA:OMY), (the “Company” or “MYM”) is looking to lead the Canadian market by establishing the gold standard in quality assurance testing of its cannabis products. MYM has hired TheraCann Canada to implement its full suite of services including ISO 17025(2005) compliance to ensure repeatable and reliable data stands behind each product label. TheraCann Canada is also providing TheraCannSYSTEM software to MYM which directly captures all testing and analysis data to better control regulatory compliance concerns and future audits by Health Canada.
With the recent announcement that the Canadian Provinces to be able to decide how cannabis will be distributed within their borders, the federal government will oversee all medical and recreational marijuana cultivation. MYM is planning to jump ahead of the curve on future legislation to focus on in-house quality assurance testing laboratories and analytics.
Brent McNiven, President of, TheraCann Canada commented: With the recent flurry of dangerous recalls in the Canadian market due, in part, to a lack of tighter government control on standards, we expect Health Canada will finally be moving to a stronger and more regulated testing procedure in advance of recreational legalization. TheraCann’s “gold standard” process build on ISO 17025 (2005) will meet or exceed all future regulations and ensure MYM is ready to excel in this rapidly expanding market.
Jonathan Fiteni, MYM CEO, commented: MYM is looking to build the industry standard in all-inclusive cannabis facilities to meet the demands of the Canadian consumer. With the anticipated start of recreational legalization coming online in the summer of 2018, MYM will be positioned to provide the safest products in the market.
MYM Nutraceuticals Inc. (CSE:MYM)(OTC:MYMMS)(FRA:OMY) is a public company trading on the Canadian Stock Exchange whose primary focus is developing high-end organic medicinal marijuana supplements and topical products. MYM also has an interest in the development of high-density farming facilities and technologies that allow MYM to expand its brand into the global market.
ABOUT THERACANN CANADA
TheraCann Canada Benchmark Corporation offers a one-stop, full-service solution for the Canadian cannabis marketplace. From regulatory applications, planning, facility design, cultivation, marketing and communications, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements. TheraCann Canada is subsidiary of TheraCann International Benchmark Corporation. More information about TheraCann is available at www.theracanncorp.com.
ON BEHALF OF THE BOARD
CEO and Director
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.